Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

2026/07/26 by Tahereh Setayesh
Medicine · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Hemoglobinopathies and Related Disorders #Blood groups and transfusion

paper · doi:10.1111/bjh.70654

Abstract

Girard et al. report a retrospective, single-centre, real-world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso-occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity-related complications, while highlighting adherence and prescription-renewal barriers in routine care. Commentary on: Girard et al. Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec. Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70622.

Citations

• The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial
• Knowledge insufficient: the management of haemoglobin SC disease
• The clinical spectrum of HbSC sickle cell disease‐not a benign condition
• A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea

Related

• Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
• Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa
• The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial
• Knowledge insufficient: the management of haemoglobin SC disease
• Management of Sickle Cell Disease